This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barrow, C. Articles by Cebon, J. Search for Related Content PubMed PubMed Citation Articles by Barrow, C. Articles by Cebon, J. Related Collections Commentary

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

Authors' Affiliations: ¹ Ludwig Institute for Cancer Research, Melbourne, Australia; ² Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia; and ³ Ludwig Institute for Cancer Research, New York, New York

Requests for reprints: Jonathan Cebon, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria 3084, Australia. Phone: 61-3-9496-5462; Fax: 61-3-9457-6698; E-mail: Jonathan.Cebon{at}ludwig.edu.au.

Purpose: Melanoma cells express antigens that can induce T-cell and antibody responses. Obtaining a detailed understanding of antigen expression in primary and metastatic melanoma is essential if these molecules are to be useful targets for immunotherapy of melanoma.

Experimental Design: Malignant melanomas (n = 586) from 426 patients were typed for antigen expression. Multiple samples were available from 86 individuals, enabling analysis of antigen expression patterns over time. Paraffin-embedded samples were tested by immunohistochemistry for the presence of the differentiation antigens: gp100, Melan-A, tyrosinase, and the "cancer/testis" antigens MAGE-A1, MAGE-A4, and NY-ESO-1.

Results: Samples were primary tumors (n = 251), lymph node metastases (n = 174), s.c. metastases (n = 71), and distant metastases (n = 90). The differentiation antigens were strongly expressed in 93% to 95% of tumors regardless of stage. In contrast, the frequency of cancer/testis antigen expression in primary tumors for MAGE-A1, MAGE-A4, and NY-ESO-1 was lower (20%, 9%, and 45%, respectively). MAGE-A1 and MAGE-A4 were acquired with advancing disease (to 51% and 44% in distant metastases, respectively) but not NY-ESO-1, which remained positive in 45%. MAGE-A1 expression was twice as prevalent in ulcerated primaries as in nonulcerated primaries (30% versus 15%; P = 0.006) and in thicker as opposed to thin melanomas (26% versus 10%; P = 0.1).

Conclusions: This large series describes patterns of antigen expression in melanoma and their evolution over time. This will help inform decisions about selection of patients and target antigens for melanoma immunotherapy clinical trials.

Commentary

Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage

F. Stephen Hodi
Clin. Cancer Res. 2006 12: 673-678. [Full Text] [PDF]

This article has been cited by other articles:

				S. Adams, D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant J. Immunol., July 1, 2008; 181(1): 776 - 784. [Abstract] [Full Text] [PDF]

				L. M. Ebert, B. S. Tan, J. Browning, S. Svobodova, S. E. Russell, N. Kirkpatrick, C. Gedye, D. Moss, S. P. Ng, D. MacGregor, et al. The Regulatory T Cell-Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells Cancer Res., April 15, 2008; 68(8): 3001 - 3009. [Abstract] [Full Text] [PDF]

				M. RAM and Y. SHOENFELD Harnessing Autoimmunity (Vitiligo) to Treat Melanoma: A Myth or Reality? Ann. N.Y. Acad. Sci., September 1, 2007; 1110(1): 410 - 425. [Abstract] [Full Text] [PDF]

				E. Fonsatti, H. J.M. Nicolay, L. Sigalotti, L. Calabro, L. Pezzani, F. Colizzi, M. Altomonte, M. Guidoboni, F. M. Marincola, and M. Maio Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2'-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications Clin. Cancer Res., June 1, 2007; 13(11): 3333 - 3338. [Abstract] [Full Text] [PDF]